Bloodstream Infections in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis Clinical Trial

Official title:

Incidence and Risk Factors of Staphylococcus Aureus Bacteremia in Patients With Rheumatoid Arthritis Compared With the General Population

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03908086
• Other study ID #: RA-SAB2018
• Status: Completed
• Start date: December 31, 1996
• Est. completion date: December 31, 2017

Study information

• Verified date: April 2019
• Source: Rigshospitalet, Denmark
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Study of incidence and risk factors of staphylococcus aureus bacteremia in patients with rheumatoid arthritis compared with the general population in a nationwide cohort of all adult members of the population from 1996 until 2017 using national registries

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6000000
• Est. completion date: December 31, 2017
• Est. primary completion date: December 31, 2017
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All members of the adult Danish population

Exclusion Criteria:

• Staphylococcus aureus bacteremia prior to inclusion.

• Rheumatoid arthritis diagnosed prior to inclusion.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Bacteremia
• Rheumatoid Arthritis
• Staphylococcus Aureus Bacteremia

Intervention

Other:
• Risk factors in RA cohort

• Risk factors in general population

Locations

Country	Name	City	State
n/a

Sponsors (4)

Lead Sponsor	Collaborator
Sabine Dieperink	Statens Serum Institut, University of Aarhus, University of Copenhagen

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of staphylococcus aureus bacteremia		0-21 years
Primary	Incidence rate ratios	Comparing rheumatoid arthritis patients with the general population	0-21 years
Secondary	Risk factors of staphylococcus aureus bacteremia	Identification of risk factors both universal to both the general population and rheumatoid arthritis (RA) cohorts and RA disease specific factors (disease duration, disease activity, smoking, joint erosions, etc.)	0-21 years